Genetic Analysis AS entered into an agreement with a leading non-disclosed global diagnostic company for the distribution of the GA-map Dysbiosis Test in Europe. GA and the diagnostic partner are now in the launch phase for selected European markets and expect this to fuel revenues from 2023. There is increasing demand for gut microbiome assessments in the private healthcare service, medical clinics, and academic research globally.

The GA-map product offering will target labs performing services to both clinical diagnostic customers and clinical research customers. The GA-map platform offers a fast turnaround lab testing service for microbiome analysis with an integrated software algorithm for immediate result presentation.